优甲乐治疗亚临床甲状腺功能减退孕妇患者的效果评价及其对妊娠结局的影响

目的 探讨优甲乐治疗妊娠期妇女亚临床甲状腺功能减退的效果及对妊娠结局的影响。方法 选取2016年11月—2017年8月某医院收治的61例亚甲状腺功能减退孕妇患者作为观察组,并选取同期在某院产检及分娩的61例健康产妇作为对照组。观察组给予优甲乐治疗,对照组给予等剂量安慰剂,比较两组入院时及分娩后促甲状腺激素(thyroid stimulating hormone,TSH)变化情况以及两组的妊娠期并发症及妊娠结局。结果 观察组治疗前TSH高于对照组,差异有统计学意义(P<0.05);观察组治疗后TSH[(1.63±0.62)IU/L]与对照组[(1.50±0.49)IU/L]比较,差异无统计学意义(P>0.05);观察组妊娠期并发症发生率(11.48%)与对照组(6.56%)比较,差异无统计学意义(P>0.05)。结论 使用优甲乐治疗可降低妊娠期妇女亚临床甲状腺功能减退患者TSH水平,减少妊娠期并发症,改善妊娠结局。

Effect of levothyroxine sodium(youjiale) on pregnant women with subclinical hypothyroidism and its influence on pregnancy outcomes

Objective To investigate the effect of levothyroxine sodium(youjiale) on pregnant women with subclinical hypothyroidism and its influence on pregnancy outcomes. Methods A total of 61 pregnant women with subclinical hypothyroidism admitted to a hospital from November 2016 to August 2017 were selected as a trial group, and 61 healthy parturients who were examined and delivered in the hospital were selected as a control group at the same time. The trial group was treated with levothyroxine sodium and the control group was given placebo. The changes of thyrotropin(thyroid stimulating hormone,TSH) were investigated and compared between two groups at the admission and after the delivery. The pregnancy complications and pregnancy outcomes were also investigated and compared between two groups. Results Before the treatment, the average TSH level was(9.55±1.78) IU/L of the trial group, which was higher than that of the control group [(1.51±0.46)IU/L], and the difference was statistically significant(P<0.05). After the treatment, the average TSH level was(1.63±0.62)IU/L of the trial group, and the level was(1.50±0.49) IU/L of the control group, and there was no statistically significant difference between two groups(P>0.05). The incidence of complications during the gestation period was 11.48% of the trial group, and the incidence was 6.56% of the control group, and there was no significant difference between two groups(P>0.05). Conclusion The levothyroxine sodium treatment can reduce TSH level and pregnancy complications, and improve pregnancy outcomes in the pregnant women with subclinical hypothyroidism.